Eli Lilly (LLY)
(Delayed Data from NYSE)
$885.55 USD
-5.52 (-0.62%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $885.00 -0.55 (-0.06%) 7:58 PM ET
1-Strong Buy of 5 1
D Value F Growth A Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$885.55 USD
-5.52 (-0.62%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $885.00 -0.55 (-0.06%) 7:58 PM ET
1-Strong Buy of 5 1
D Value F Growth A Momentum F VGM
Zacks News
Wall Street Regains Momentum on Vaccine Hopes: 5 Top Picks
by Nalak Das
Investment in momentum stocks with a favorable Zacks Rank may be fruitful in the near term. These include Fulgent Genetics (FLGT), II-VI (IIVI), General Motors (GM), Flagstar Bancorp (FBC) and Lear (LEA).
Merck's (MRK) Keytruda Gets FDA Nod for Severe Breast Cancer
by Zacks Equity Research
The FDA approves Merck's (MRK) Keytruda combo for the treatment of patients with metastatic triple-negative breast cancer. This marks the first nod for Keytruda in the breast cancer setting.
Pharma Stock Roundup: PFE Coronavirus Data, FDA Emergency Tag for LLY COVID-19 Drug
by Kinjel Shah
Eli Lilly (LLY) and Pfizer (PFE) provide updates on their coronavirus vaccine/antibody candidates.
3 Reasons to Bet on Healthcare ETFs
by Sanghamitra Saha
The broader medical sector should be in the spotlight now on hopes of a coronavirus vaccine and the likelihood of a divided congress.
Stock Market News for Nov 11, 2020
by Zacks Equity Research
Wall Street had a mixed day on Tuesday with investor rushing to sell of tech stocks that had had dream run during the virus-induced lockdown, while they put money on sectors that took a beating during the pandemic.
Vaccine Hopes Rise as Pharma Giants Inch Closer Toward Success
by Ritujay Ghosh
Stocks of Eli Lilly and Company (LLY), Pfizer, Inc. (PFE) and Moderna, Inc. (MRNA) have been in focus since the coronavirus outbreak as they have been the frontrunners in the vaccine race.
Reopening Stocks Gain on Vaccine Hopes
by Zacks Equity Research
Reopening Stocks Gain on Vaccine Hopes
Biohaven (BHVN) Q3 Earnings Miss, Nurtec Uptake Promising
by Zacks Equity Research
Biohaven's (BHVN) recently approved migraine drug, Nurtec ODT, continues to demonstrate strong launch uptake.
Blue Chips & Tech Going Separate Directions: PFE, GOOGL, FB, LLY & More
by Mark Vickery
The last time we saw the Dow surge strongly ahead while the Nasdaq dipped into the red was back in 2000, when the tech bubble of the pre-Y2K market began to burst.
Radius' (RDUS) Q3 Loss Matches Estimates, Revenues Miss
by Zacks Equity Research
Radius (RDUS) reports an in-line loss but misses sales estimates in the third quarter.
Nektar (NKTR) Stock Up 3% on Q3 Earnings and Revenue Beat
by Zacks Equity Research
Nektar (NKTR) reports encouraging third-quarter 2020 results. Enrollment in clinical studies back on track.
Incyte (INCY) Q3 Earnings & Sales Miss, Jakafi Demand Strong
by Zacks Equity Research
Incyte (INCY) misses earnings and sales expectations in the third quarter. However, the company's lead drug, Jakafi, reports encouraging growth.
The Zacks Analyst Blog Highlights: Google, Johnson & Johnson, Union Pacific Corp, Eli Lilly, Charter Communications and Anheuser-Busch InBev
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Google, Johnson & Johnson, Union Pacific Corp, Eli Lilly, Charter Communications and Anheuser-Busch InBev
What Awaits AVEO Pharmaceuticals (AVEO) in Q3 Earnings?
by Zacks Equity Research
On AVEO Pharmaceuticals' (AVEO) third-quarter earnings call, investor focus will be on the updates related to its NDA that seeks an approval for tivozanib to treat RCC in the United States.
Top Research Reports for Alphabet, Johnson & Johnson & Union Pacific
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Alphabet (GOOGL), Johnson & Johnson (JNJ) and Union Pacific (UNP).
The Zacks Analyst Blog Highlights: Eli Lilly, Merck, Pfizer, Novartis, AstraZeneca and J&J
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Eli Lilly, Merck, Pfizer, Novartis, AstraZeneca and J&J
Pharma Stock Roundup: Q3 Earnings, Resumption of AZN/JNJ Coronavirus Vaccine Study
by Kinjel Shah
Eli Lilly (LLY), Merck (MRK), Pfizer (PFE), Novartis (NVS) and others release Q3 results
Novo Nordisk's (NVO) Q3 Earnings Beat Estimates, Sales Miss
by Zacks Equity Research
Novo Nordisk (NVO) misses earnings and sales estimates in the third quarter of 2020.
Gilead (GILD) Beats on Q3 Earnings & Sales, Lowers '20 View
by Zacks Equity Research
Gilead (GILD) reports better-than-expected results for the third quarter owing to Veklury sales. However, the company lowers annual guidance.
United Therapeutics (UTHR) Q3 Earnings & Sales Beat Estimates
by Zacks Equity Research
United Therapeutics' (UTHR) third-quarter earnings and sales beat estimates. Higher sales of Orenitram and Tyvaso offset lower sales of Remodulin and Adcirca.
Company News for Oct 28, 2020
by Zacks Equity Research
Companies In The News Are: PFE, LLY, MMM, SHW.
Lilly (LLY) Q3 Earnings & Revenues Lag Estimates, Stock Down
by Zacks Equity Research
Eli Lilly (LLY) misses on both earnings and sales for the third quarter. The company reiterates its revenue guidance for 2020.
Eli Lilly (LLY) Q3 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Lilly (LLY) delivered earnings and revenue surprises of -12.50% and -2.36%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Roche (RHHBY) Inks Deal to Develop Oral Coronavirus Treatment
by Zacks Equity Research
Roche (RHHBY) signs a contract with privately-held Atea Pharmaceuticals for jointly developing AT-527, an oral treatment for COVID-19 patients.
Healthcare to Post Solid Q3 Earnings Growth: ETFs in Focus
by Sweta Killa
The healthcare is expected to witness substantial earnings growth of 5.1% in the third quarter, representing the second strongest sector this earnings season.